TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.02.840PMID 16043829
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

  2004cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  2004cited by this paper
• Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).

  2004cited by this paper
• Novel Agents in the Treatment of Lung Cancer

  2004cited by this paper
• A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

  2004cited by this paper
• Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

  2004cited by this paper
• Novel agents in the treatment of lung cancer: conference summary statement.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

  2004cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Corrigendum to “Cancer burden in the year 2000. The global picture” [European Journal of Cancer,37(Suppl. 8) (2001) S4–S66]

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Influence of unrecognized molecular heterogeneity on randomized clinical trials.

  2002cited by this paper
• Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers.

  2001cited by this paper
• Cancer burden in the year 2000. The global picture.

  2001cited by this paper
• Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

  2001cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• DECLARATION OF HELSINKI.

  1964cited by this paper

• Navigating the Evolving Landscape of EGFR-Mutated NSCLC.

  2026cites this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).

  2026cites this paper
• 50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic.

  2025cites this paper
• A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.

  2025cites this paper
• Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells

  2025cites this paper
• Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

  2024cites this paper
• Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer

  2024cites this paper
• Identification of immune-associated biomarker for predicting lung adenocarcinoma: bioinformatics analysis and experiment verification of PTK6

  2024cites this paper
• Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status

  2024cites this paper
• A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: An update.

  2024cites this paper
• Circular RNA CircRNA-0000520 promotes non-small cell lung cancer progression through sponging microRNA-521

  2024cites this paper
• Evolving therapeutic landscape of EGFR-TKIs in NSCLC

  2024cites this paper
• Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases

  2023cites this paper
• Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.

  2023cites this paper
• Regulation of epithelial-mesenchymal transition in retinal pigment epithelium and its associated cellular signaling cascades: an updated review

  2023cites this paper
• The pharmacological and biological importance of EZH2 signaling in lung cancer.

  2023cites this paper
• Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase

  2022cites this paper
• Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting

  2022cites this paper
• Bioinformatic Analysis Identifies of Potential miRNA-mRNA Regulatory Networks Involved in the Pathogenesis of Lung Cancer

  2022cites this paper
• Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

  2022cites this paper
• Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

  2022cites this paper
• The intervention of epithelial-mesenchymal transition in homeostasis of human retinal pigment epithelial cells: a review

  2022cites this paper
• Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer.

  2022cites this paper
• Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity

  2022cites this paper
• Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence

  2022cites this paper
• The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer

  2022cites this paper
• Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

  2022cites this paper
• “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients

  2022cites this paper
• The Profile and Clinical Significance of ITGB2 Expression in Non-Small-Cell Lung Cancer

  2022cites this paper
• The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer

  2021cites this paper
• Systemic Therapy for Mutation-Driven NSCLC.

  2021cites this paper
• Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy

  2021cites this paper
• Impact Analysis of miR-1253 on Lung Cancer Progression Through Targeted Regulation of ANXA3

  2021cites this paper
• Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma

  2021cites this paper
• Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

  2021cites this paper
• Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations

  2021cites this paper
• Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.

  2021cites this paper
• EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.

  2021cites this paper
• Immunotherapy related pericardial effusion on chest CT.

  2021cites this paper
• Эффективность интегрированной химиотерапии с ингибиторами тирозинкиназы рецептора EGFR у пациентов с немелкоклеточным раком легкого и активирующей мутацией гена EGFR.

  2021cites this paper
• Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

  2021cites this paper
• Update on recent key publications in lung oncology: picking up speed

  2021cites this paper
• Toward personalized treatment approaches for non-small-cell lung cancer

  2021cites this paper
• Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?

  2021cites this paper
• Recent Advances and Future Perspective of DC-Based Therapy in NSCLC

  2021cites this paper
• First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

  2021cites this paper
• Cost Effectiveness Analysis Of Gefitinib Plus Chemotherapy Versus Gefitinib Alone For Advanced Non-Small-Cell Lung Cancer With EGFR Mutations In China

  2021cites this paper
• Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo

  2021cites this paper
• Overcoming therapy resistance in EGFR-mutant lung cancer

  2021cites this paper
• Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

  2021cites this paper
• Cytokine and epigenetic regulation of programmed death‐ligand 1 in stem cell differentiation and cancer cell plasticity

  2021cites this paper
• Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

  2021cites this paper
• Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.

  2020cites this paper
• Targeted Therapy for Non-Small Cell Lung Cancer

  2020cites this paper
• Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations

  2020cites this paper
• miR-574-5p Targets FOXN3 to Regulate the Invasion of Nasopharyngeal Carcinoma Cells via Wnt/β-Catenin Pathway

  2020cites this paper
• Pharmacokinetics and Renal Tissue Distribution of Erlotinib in a Rat Model of Autosomal Dominant Polycystic Kidney Disease

  2020cites this paper
• Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed

  2020cites this paper
• Review of Evaluation Methods of Tumor Pharmacodynamics

  2020cites this paper
• Systemic Therapy of Brain Metastases: Lung Cancer

  2020cites this paper
• Metronomic chemotherapy in non-small cell lung cancer.

  2020cites this paper
• First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients.

  2020cites this paper
• A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

  2020cites this paper
• Combination Compositions Composed of l-Glutamine and Si-Jun-Zi-Tang Might Be a Preferable Choice for 5-Fluorouracil-Induced Intestinal Mucositis: An Exploration in a Mouse Model

  2020influential citation
• Madusha Meemanage1 · Lindsay C. Spender1 · Diane Collinson2 · Joanna Iannetta1 · Pranavi Challapalli1 · Julie Turbitt2 · Caroline Clark2 · Mark Baxter1 · Graeme Murray3 · Shaun Walsh4 · Zofia Miedzybrodzka2 · Russell D. Petty1

  2020cites this paper
• Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.

  2020cites this paper
• Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib

  2020cites this paper
• KRAS: From undruggable to a druggable Cancer Target.

  2020cites this paper
• A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer

  2020cites this paper
• A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1

  2020cites this paper
• Medical management of brain metastases

  2020cites this paper
• The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression-free survival in patients with advanced EGFR-mutated NSCLC.

  2020cites this paper
• Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner

  2020cites this paper
• The top 100 cited articles in lung cancer – a bibliometric analysis

  2020cites this paper
• Acquired Resistance in Lung Cancer

  2020cites this paper
• Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients

  2020cites this paper
• Pulmonary Complications of Anticancer Treatment

  2020cites this paper
• First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2020cites this paper
• Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913

  2020cites this paper
• Cancer of the Lung

  2020cites this paper
• Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer

  2020cites this paper
• Racial Disparities in Survival Among Advanced Non-Small Cell Lung Cancer Patients First-Treated with The Combination of Paclitaxel and Platinum

  2020cites this paper
• Clinical question : What is the optimal systemic therapy for stage IV inoperable NSCLC ?

  2020cites this paper
• Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

  2020cites this paper
• Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity

  2020cites this paper
• Current Concepts in the Use of Cisplatin: A Historical Perspective and Its Recent Advances in the Treatment of Non-Small Cell Lung Cancer

  2019cites this paper
• Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

  2019cites this paper
• Эрлотиниб в комбинированной терапии распространенной аденокарциномы легкого при наличии мутации гена EGFR

  2019cites this paper
• EGFR Targeted Therapy

  2019cites this paper
• The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy☆

  2019cites this paper
• Targeted Therapies in Non-small-Cell Lung Cancer.

  2019cites this paper
• Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).

  2019cites this paper
• Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.

  2019cites this paper
• Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers

  2019cites this paper
• Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

  2019cites this paper
• Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.

  2019cites this paper
• Management of Locally Advanced Lung Cancer

  2019cites this paper
• Principles of Dose, Schedule, and Combination Therapy

  2019cites this paper
• EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

  2019cites this paper
• Mutaciones del gen del receptor del factor de crecimiento epidérmico (egfr) en pacientes con carcinoma no microcítico de pulmón: cribado poblacional, significado predictivo y pronóstico y estrategias terapéuticas a la progresión

  2019cites this paper